Table 1.
Baseline characteristics.
| Characteristic | Level | Anakinra (N = 14) | Placebo (N = 11) |
|---|---|---|---|
| Age (years) | Mean (SD) Minimum-Maximum |
70 (11.5) 57–88 |
62 (14.6) 38–85 |
| Sex | |||
| Male | N (%) | 8 (57%) | 5 (45%) |
| Female | N (%) | 6 (43%) | 6 (55%) |
| Ethnicity | |||
| White | N (%) | 12 (86%) | 9 (82%) |
| Other | N (%) | 2 (14%) | 2 (18%) |
| Premorbid mRS | |||
| 0 | N (%) | 8 (57%) | 7 (64%) |
| 1 | N (%) | 4 (29%) | 3 (27%) |
| 2 | N (%) | 1 (7%) | 0 |
| 3 | N (%) | 1 (7%) | 1 (9%) |
| 4 | N (%) | 0 | 0 |
| 5 | N (%) | 0 | 0 |
| Time between onset and arrival in hospital (hours) | Median (IQR) Minimum-Maximum |
1.6 (1.0, 4) 0.9–5.6 |
1.8 (1.3, 2.0) 1.1–4.8 |
| Systolic Blood Pressure (mmHg) | Mean (SD) Minimum-Maximum |
160.7 (30.7) 130–237 |
158.7 (22.3) 127–203 |
| Pre-randomisation Glasgow Coma Scale score | Median (IQR) Minimum-Maximum |
14 (11, 15) 8–15 |
15 (14, 15) 8–15 |
| Glasgow Coma Score Classification | |||
| Mild (14–15) | N (%) | 9 (64%) | 9 (82%) |
| Moderate (9–13) | N (%) | 4 (29%) | 1 (9%) |
| Severe (3–8) | N (%) | 1 (7%) | 1 (9%) |
| NIHSS on admission/baseline | Median (IQR) Minimum-Maximum |
12.5 (9, 19) 2–26 |
6 (3, 12) 1–20 |
| NIHSS on admission/baseline | |||
| Minor (1–4) | N (%) | 1 (7%) | 5 (45%) |
| Moderate (5–15) | N (%) | 8 (57%) | 4 (36%) |
| Moderate-severe (16–20) | N (%) | 3 (21%) | 2 (18%) |
| Severe (21–40) | N (%) | 2 (14%) | 0 |
| ICH Volume (mL) | Median (IQR) Minimum-Maximum |
12.6 (4.8, 17.9) 1.4–41.8 |
5.5 (2.1, 10.9) 1.1–45.0 |
| Intraventricular haemorrhage | N (%) | 4 (29%) | 1 (9%) |
| Haematoma location | |||
| Deep | N (%) | 7 (50%) | 8 (73%) |
| Lobar | N (%) | 7 (50%) | 3 (27%) |
| Hypertension | |||
| Yes | N (%) | 7 (50%) | 5 (45%) |
| No | N (%) | 7 (50%) | 5 (45%) |
| Unknown | N (%) | 0 | 1 (9%) |
| Type 2 Diabetes | |||
| Yes | N (%) | 0 | 1 (9%) |
| No | N (%) | 14 (100%) | 10 (91%) |
| Atrial fibrillation | |||
| Yes | N (%) | 3 (21%) | 3 (27%) |
| No | N (%) | 0 | 1 (9%) |
| Missing | N (%) | 11 (79%) | 7 (64%) |
| Prior venous thromboembolism | |||
| Yes | N (%) | 1 (7%) | 1 (9%) |
| No | N (%) | 2 (14%) | 3 (27%) |
| Missing | N (%) | 11 (79%) | 7 (64%) |
| Use of anticoagulants | |||
| Warfarin | N (%) | 3 (21%) | 0 |
| Rivaroxaban | N (%) | 0 | 2 (18%) |
| Apixaban | N (%) | 0 | 2 (18%) |
| Symptom onset to randomisation (h) | Mean (SD) Minimum-Maximu |
4.6 (1.7) 2.7–7.9 |
4.8 (1.7) 3.3–6.2 |
| Randomisation to treatment (min) | Mean (SD) Minimum-Maximum |
33 (26) 3–108 |
28 (18) 12–50 |